Status: Recruiting
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.
Participants needed: 150
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: EpimAb Biotherapeutics (Suzhou)Co., Ltd.Updated: Mar 3, 2025Locations: 10
Eligibility criteria
Willing and able to provide signed and dated informed consent prior to any study... [+7]
Prior treatment with any agent targeting ROR1. [+4]